ARQTArcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 8.46 $ -0.12 (-1.4 %)    

Friday, 26-Apr-2024 15:59:59 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 8.47
$ 8.55
$ 0.00 x 0
$ 8.47 x 200
$ 8.39 - $ 8.84
$ 1.76 - $ 15.21
2,164,430
na
522.83M
$ 0.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-22-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-16-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-16-price-target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 arcutis-announces-acceptance-of-late-breaking-abstract-in-atopic-dermatitis-among-five-new-topical-roflumilast-data-being-presented-at-the-american-academy-of-dermatology-annual-meeting

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...

 arcutis-prices-150m-public-offering-of-15789474-common-shares-at-950share

The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting ...

 arcutis-and-sato-announce-strategic-collaboration-and-licensing-agreement-for-topical-roflumilast-in-japan-the-arcutis-to-receive-a-25m-upfront-payment-and-is-eligible-to-receive-potential-development-and-commercial-milestone-payments-totaling-40m

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone pay...

 goldman-sachs-maintains-neutral-on-arcutis-biotherapeutics-raises-price-target-to-11

Goldman Sachs analyst Jonathan Block maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price tar...

 mizuho-reiterates-buy-on-arcutis-biotherapeutics-raises-price-target-to-17

Mizuho analyst Uy Ear reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $16 to $17.

 needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-16

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

 arcutis-biotherapeutics-q4-2023-gaap-eps-072-beats-076-estimate-sales-1353m-beat-1134m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate ...

 arcutis-biotherapeutics-q4-gaap-eps-072-beats-078-estimate-sales-1353m-beat-1134m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate ...

 earnings-scheduled-for-february-27-2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

 maxlinear-reports-q4-results-joins-ing-wolfspeed-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION